Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Abbott takes global view: Abbott Laboratories expects tighter spending on consumer products to affect its U.S. nutritional business more than international sales, which were a key driver in the firm's latest earnings period. "I think any concern of economic slowdown is a little more U.S.-focused," Chief Financial Officer Thomas Freyman says Oct. 15 during Abbott's third-quarter earnings call. Consumers see both pediatric and adult nutritional products "as more core to their essential as opposed to discretionary-type items," he adds. The Abbott Park, Ill.-based firm's international nutritional sales increased 22.2 percent to $629 million, but 5.5 percent of the growth was from the positive impact of currency exchange, according to a same-day release. Worldwide nutritional sales grew 14.5 percent to $1.26 billion, with U.S. sales up 7.8 percent to $633 million. The company says pediatric products accounted for $668 million of the nutritional total, a 10.8 percent increase, and adult products reached $584 million, up 19.1 percent. Abbott expects to start manufacturing nutritionals at a Singapore facility in early 2009 (1"The Tan Sheet" Oct. 22, 2007, p. 9). "It will be a much more convenient way to supply the Asian market, which currently we're supplying out of our European facilities," Investor Relations VP John Thomas says

You may also be interested in...



Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

Topics

UsernamePublicRestriction

Register

PS102223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel